GSK (NYSE:GSK) Stock Rating Lowered by StockNews.com

GSK (NYSE:GSKGet Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Tuesday.

Several other analysts have also recently commented on GSK. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and dropped their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

Read Our Latest Research Report on GSK

GSK Price Performance

NYSE:GSK opened at $33.46 on Tuesday. The stock has a 50 day moving average of $34.02 and a two-hundred day moving average of $37.97. GSK has a 12 month low of $31.72 and a 12 month high of $45.92. The firm has a market cap of $69.34 billion, a P/E ratio of 21.72, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98.

Institutional Investors Weigh In On GSK

Several hedge funds and other institutional investors have recently bought and sold shares of GSK. Eastern Bank acquired a new stake in GSK during the third quarter worth $26,000. Sunbelt Securities Inc. increased its position in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the last quarter. Concord Wealth Partners raised its holdings in GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 547 shares during the period. ST Germain D J Co. Inc. lifted its position in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the last quarter. Finally, Fortitude Family Office LLC purchased a new position in GSK during the third quarter worth about $42,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

See Also

Analyst Recommendations for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.